Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699665 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL12240327 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL2614692 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL10163545 | 0.89 | PYGM (0.61) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL15336891 | 0.89 | PYGM (0.61) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL13184452 | 0.85 | PYGM (0.56) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL20419026 | 0.82 | PYGM (0.54) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL20072701 | 0.80 | TK2 (0.47) | PYGMTK2 | |
| SCHEMBL12240330 | 0.79 | PYGM (0.56) | PYGMP2RY6DNPH1TK2 | |
| SCHEMBL1699647 | 0.79 | PYGM (0.56) | PYGMP2RY6DNPH1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128760-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120088815-A1 | Modified Oligonucleotide and Its Preparation and Application | BIOMICS BIOTECHNOLOGIES CO. LTD (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088815-A1 | Modified Oligonucleotide and Its Preparation and Application | UNG, NSUN2, UPF1 | PYGM 2272/4885P2RY6 1545/4885P2RY2 2848/4885 |
| US-20120128760-A1 | LIPID COMPOSITIONS | SGMS1, SGMS2, LIPA | PYGM 4222/4885P2RY6 4671/4885P2RY2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.